Monoclonal Antibodies Targeting Open Prothrombin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulants, such as heparin and warfarin, have limitations including variability in response, binding to multiple plasma proteins, and complications in pharmacokinetics, necessitating the development of more effective anticoagulants.
Innovation Solution
The development of antigen-binding proteins, including monoclonal antibodies that specifically bind to the open form of prothrombin, reducing its conversion to thrombin. These antibodies target specific residues in the kringle-1 domain of prothrombin, such as E85, L88, R90, S91, R92, Y93, Q110, and E111, to achieve anticoagulant effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticoagulants (heparin, warfarin) are used, then blood clotting is inhibited, but response variability and binding to multiple plasma proteins occur
Solution Approach 1:
The patent applies local quality by designing monoclonal antibodies with highly specific binding sites targeting only the open form of prothrombin in a localized region (kringle-1 domain), rather than having broad-spectrum binding like conventional anticoagulants. This specificity eliminates non-specific binding to other plasma proteins while maintaining reliable anticoagulant effect through focused molecular interaction.
Solution Approach 2:
The patent uses copying by creating monoclonal antibodies that are molecular copies of natural immune responses against prothrombin. These antibodies are generated through immunization and cloning processes, producing identical molecular structures that consistently target the specific conformational epitope on open prothrombin, thereby eliminating response variability inherent in conventional anticoagulants.
2Reliability
If conventional anticoagulants are used, then thrombin generation is reduced, but pharmacokinetic complications arise
Solution Approach 1:
The patent replaces the complex pharmacokinetic system of conventional anticoagulants (which involve multiple plasma protein bindings, variable metabolism, and complex dosing) with a simpler molecular mechanism. The monoclonal antibodies directly bind to and neutralize open prothrombin through specific molecular recognition, eliminating the need for complex pharmacokinetic management while maintaining reliable anticoagulant efficacy.
3Manufacturing precision
If monoclonal antibodies targeting open prothrombin are developed, then specificity and anticoagulant effect are improved, but manufacturing and characterization complexity increases
Solution Approach 1:
The patent applies preliminary action by performing extensive in silico modeling and in vitro characterization experiments during the development phase. The monoclonal antibodies are pre-characterized for binding affinity, specificity, and functional activity before clinical use, ensuring manufacturing precision is achieved from the outset. This preliminary characterization reduces the need for complex ongoing monitoring and adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antigen-binding proteins effectively decrease thrombin generation, thereby reducing the risk of blood clots and thrombosis, and can be used to treat various conditions including deep vein thrombosis, pulmonary embolism, and atrial fibrillation.
Implementation Method 1
antigen-binding proteins including monoclonal antibodies against prothrombin and fragments and conjugates thereof, which bind to the open form of prothrombin and decrease conversion of prothrombin to thrombin
Data Source
AI summary
Antigen-binding proteins including monoclonal antibodies (mAbs) against prothrombin, which bind to the open form of prothrombin and decrease conversion of prothrombin to thrombin are provided. Antibody fragments and conjugates are also provided. Anticoagulant pharmaceutical compositions based on the monoclonal antibodies against prothrombin and fragments and conjugates thereof are also provided, along with methods for treating and preventing blood clots and for reducing thrombin generation in patients.